Bioventus Inc.BVSNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
5Y CAGR+14.2%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

5Y CAGR
+14.2%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
1.9x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$105.56M+169.1%
2024$39.22M+270.0%
2023$-23.07M+81.0%
2022$-121.61M-367.4%
2021$45.48M-16.3%
2020$54.31M-11.8%
2019$61.58M+13.0%
2018$54.52M-8.9%
2017$59.85M+35.9%
2016$44.05M-